Nutex Health Reports $11.8M Net Income for Q4 2025
Net income attributable to Nutex Health for the three months ended December 31, 2025 was $11.8M as compared to net income attributable to Nutex Health of $61.6M for the same period in 2024. The company attributes the $105.9M revenue decrease primarily to two items: a one-time $55.0M cumulative true-up of arbitration claims determined ineligible , with the associated catch-up reduced the number of active disputes compared to the same period in 2024 and contributed to lower net revenue for the quarter; and arbitration revenues of $69.0M relating to submissions during 3Q24 that were recorded in 4Q24. After considering the impact of the adjustments above, 4Q25 revenue would be $206.7M and 4Q24 revenue would be $188.6M, a revenue increase of $18.1M. "We are continuing to add to a record year with 82% revenue growth, Adjusted EBITDA attributable to Nutex Health of $259.6M, a 126.4% increase in gross profit and a record high cash balance of $185.6M," stated CFO Jon Bates. "Compared to 2024, we delivered improvements across nearly all key financial metrics. During 2025 and early 2026, we successfully opened three new micro-hospitals, further expanding our national footprint. In addition, both ER visits and inpatient admissions grew year over year, reflecting increased demand and strengthened operational performance," stated CEO Tom Vo. "Looking ahead, we are well positioned for continued growth through a balanced strategy that includes both de novo hospital development and increased patient volumes across our existing facilities."
Trade with 70% Backtested Accuracy
Analyst Views on NUTX
About NUTX
About the author

- Significant Stock Drop: Nutex Health's shares plummeted over 24% in pre-market trading on March 6, 2026, indicating severe market concerns regarding its financial health following the release of its fourth quarter and full-year 2025 results.
- Reimbursement Claim Issues: The company disclosed that many out-of-network reimbursement claims submitted through the federal Independent Dispute Resolution process were deemed ineligible, resulting in a one-time $55 million cumulative true-up for 18,950 arbitration claims, which could undermine investor confidence.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating Nutex Health for potential violations of federal securities laws, and investors who suffered losses exceeding $50,000 may participate in litigation, further exacerbating negative sentiment in the market.
- Investor Loss Risk: Given the company's legal scrutiny and financial uncertainties, investors may face heightened risk of losses, particularly if Nutex fails to effectively address its reimbursement claim issues, potentially impacting its future financing capabilities and market performance.
- Stock Plunge: Nutex Health's shares fell over 24% in pre-market trading on March 6, 2026, indicating severe market concerns regarding its financial health following the release of its Q4 and full-year 2025 results.
- Reimbursement Claim Issues: The company disclosed that many out-of-network reimbursement claims submitted through the federal Independent Dispute Resolution process were deemed ineligible, leading to diminished investor confidence in future revenues and potential market share loss.
- Arbitration Claim Adjustment: Nutex reported a one-time $55 million cumulative adjustment involving 18,950 arbitration claims that were ruled ineligible, significantly impacting the company's finances and potentially triggering further legal actions.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether Nutex Health violated federal securities laws, and investors who suffered losses exceeding $50,000 may participate in this investigation, further exacerbating market uncertainty.
- Market Weakness: The S&P 500 index fell by 1.33%, and the Dow Jones Industrial Average hit a 3.5-month low, reflecting investor concerns over the Middle East conflict potentially driving energy prices higher and sparking inflation risks, which dampens market confidence.
- Disappointing Employment Data: The US nonfarm payrolls unexpectedly dropped by 92,000 in February, with the unemployment rate rising to 4.4%, indicating a weakening labor market that raises doubts about economic health and may lead the Fed to adopt a more cautious approach in future policy adjustments.
- Surge in Energy Prices: WTI crude oil prices surged over 12% to a 2.5-year high as the ongoing Middle East conflict exacerbates supply concerns, which is expected to push global oil prices even higher, impacting profitability across related sectors.
- Corporate Earnings Resilience: Despite the overall market decline, 74% of S&P 500 companies reported earnings that exceeded expectations, with Q4 earnings growth projected at 8.4%, demonstrating a degree of resilience among businesses that may support future market recovery.
- Financial Performance Decline: Nutex Health reported a revenue decrease of $105.9 million to $151.7 million for Q4 2025, partly due to a $55 million cumulative true-up of arbitration claims, indicating significant financial pressure and compliance risks for the company.
- Arbitration Claims Impact: The report highlighted that 18,950 arbitration claims were deemed ineligible under the IDR process, leading to a one-time financial adjustment, which reflects potential deficiencies in the company's legal handling and may undermine investor confidence.
- Stock Price Reaction: Following the financial results announcement, Nutex Health's stock price dropped, signaling increasing market concerns regarding the company's financial health and potentially leading to pessimistic expectations about future performance.
- Legal Consultation Opportunity: Holzer & Holzer is investigating whether Nutex Health complied with federal securities laws and encourages affected investors to reach out to discuss their legal rights, highlighting the potential legal risks and the need for investor protection.
- Market Decline: The S&P 500 index fell by 0.95%, the Dow Jones Industrial Average by 1.00%, and the Nasdaq 100 by 0.76%, reflecting market concerns that the ongoing Middle East war could drive energy prices higher, leading to inflation.
- Weak Employment Data: U.S. nonfarm payrolls unexpectedly dropped by 92,000 in February, with the unemployment rate rising to 4.4%, indicating a deteriorating labor market and exacerbating fears of an economic slowdown.
- Surge in Energy Prices: WTI crude oil prices surged over 9% to a 2.25-year high due to the ongoing conflict in the Middle East, raising inflation expectations and diminishing investor confidence in the stock market.
- Corporate Earnings Performance: Despite the overall market weakness, 73% of S&P 500 companies exceeded earnings expectations, with Q4 earnings projected to grow by 8.4%, demonstrating resilience among some firms that may provide future market support.
- Market Decline: The S&P 500 index fell by 1.68%, with the Dow Jones Industrial Average hitting a 3.5-month low, reflecting market concerns that the Middle East war could drive energy prices higher, leading to inflation risks.
- Weak Labor Market: U.S. nonfarm payrolls unexpectedly dropped by 92,000 in February, with the unemployment rate rising to 4.4%, indicating a labor market health below expectations, which could slow consumer spending and impact economic growth.
- Surging Energy Prices: Amid escalating tensions in the Middle East, WTI crude prices surged over 7% to a 2.25-year high, likely pushing global fuel prices higher, which could affect airline profits and consumer spending.
- Optimistic Corporate Earnings: Despite market volatility, over 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, indicating strong corporate profitability, and S&P 500 earnings growth is projected to reach 8.4% for Q4.











